GlassScriptPhysician profile
James L Lamb
NPI 1316655178
$2,571.40
in general payments reported to CMS, 2019-2025
23 companies · $682 in 2025
The $682 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.47 · 2023: $640 · 2024: $1,160 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.31 | 2023-2025 | |
| Gilead Sciences, INC. | $391.20 | 2023-2025 | Epclusa |
| Alkermes, INC. | $326.73 | 2024-2025 | Vivitrol, Aristada, Lybalvi |
| Inari Medical, INC. | $211.82 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Indivior INC. | $164.20 | 2023-2024 | Sublocade, Perseris |
| Angiodynamics, INC. | $152.17 | 2023-2025 | Alphavac, Angiovac, Smart Port Ct |
| Otsuka America Pharmaceutical, INC. | $148.65 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.53 | 2024-2025 | Caplyta |
| Boston Scientific Corporation | $120.49 | 2022-2023 | |
| Lundbeck LLC | $107.11 | 2023-2025 | Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $74.79 | 2024-2025 | Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $54.02 | 2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $51.10 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $46.21 | 2025 | Secuado, Xelstrym |
| Axsome Therapeutics, INC. | $43.35 | 2025 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.49 | 2025 | |
| Lilly USA, LLC | $18.05 | 2024 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $16.28 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $15.55 | 2025 | Trelegy Ellipta |
| Dexcom, INC. | $14.74 | 2025 | Dexcom G6 Transmitter |
| Orexo US, INC. | $14.24 | 2025 | Zubsolv |
| Janssen Pharmaceuticals, INC | $14.11 | 2024 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $13.26 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.